What they were paid
Coherus Oncology Director Compensation Table · the one fiscal year held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $77,500 | $0 | $61,667 | $0 | $139,167 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Coherus Oncology, Inc. DEF 14A filed April 20, 2026, accession 0001104659-26-045251, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025Coherus Oncology pays directors a $50,000 cash retainer and $61,667 in Options.
Committees
FY2025 · as the proxy prints themAudit (Chair)
The rest of the Coherus Oncology board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Ali J. Satvat | Independent Director | $144,167 |
| Charles W. Newton | Independent Director | $144,167 |
| Dennis M. Lanfear | Chair of the Board | $0 |
| Georgia Erbez | Independent Director | $134,167 |
| Jill O'Donnell-Tormey, Ph.D | Independent Director | $116,667 |
| Lee N. Newcomer, MD | Independent Director | $121,667 |
| Mats L. Wahlström | Lead Independent Director | $191,667 |
| Michael Ryan | Independent Director | $131,042 |
The full Coherus Oncology compensation record
free company briefThis page is one director within Coherus Oncology's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat